Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

3selected
Comparing 3 of 3 drugs
× × ×
Change selection
3 drug columns · use arrows or scrollbar
Field ACETAZOLAMIDE
Renal · Renal · Level 3
FRUSEMIDE
Renal · Renal · Level 1
SPIRONOLACTONE
Renal · Renal · Level 3
Mechanism of action

Diuresis
Reversible, non-competitive inhibitor of carbonic anhydrase
PCT: ↓H+ and HCO3- prodn
↓ cytosol H+ → ↓Na+ reabs in PCT→ ↑H2O loss
↓cytosol HCO3→↑luminal HCO3→ H2O diffusion with HCO3 ,Na, K to urine
Eye: ↓Na pump, ↓AH formation

Diuresis
Inhibition of active chloride ion reabsorption in PCT and ascending limb of LoH
↓ reabsorption of NaCl → ↓ tonicity in the renal medulla → ↓water reabsorption and diuresis.
Other effects are mediated by the induction of the COX-2 enzyme which assists in synthesis of prostaglandins.

Acts in the DCT.
It is a competitive antagonist of aldosterone at the receptors in the DCT.
Decreased Na reabsorption and increased K reabsorption
= Increased Na loss and Diuresis.

Physiological effects

Metabolic: Acidosis via ↑ excretion of bicarb (and reabsorption of Cl)
Resp: ↑MV → comp resp alk
CNS: anticonvulsant properties, ↓ CSF and IOP by ↓d formation GIT: ↓ Pancreatic and gastric
GU: mild diuresis, Na retention

Pulmonary and systemic vasodilation
Diuresis ↑ RBF and ↑ corticomedullary blood flow
↓O₂ demand in the LoH (ischaemic
protection)

Sedation and muscle weakness (due to electrolyte abnm)
Antihypertensive,
Diuresis (in 3-4 days)
Potassium retention
Anti-androgenic effect- inhbn of ovarian androgen secretion
↑renal Ca excr, ↑plasma urea
Reversible hyperchloraemic MA

Absorption

IV/PO
PO BA = 100%

PO/IV/SL/IM. PO BA 50% Onset PO/SL 30-60mins, IV 5 mins .
Dur PO/SL 6-8hrs, IV 2hrs

PO - BA 70%, extensive 1st pass metb. Onset 3-4hrs, dur upto 3 days

Distribution

Lip sol: crosses BBB

— —
Protein binding

70-90%

91-99% (Albumin)

90%

Volume of distribution —

0.1L/kg

—
Metabolism

Not metabolised

Renal to glucuronide
Minimal hepatic

Hepatic: Rapidly and extensively metabolised by deacetylation and dethiolation. Active metab: canrenone and 7-alpha-spirolactone

Excretion

Unchanged in urine

80% unchanged in urine

Urine and faeces

Half-life

6-9hrs

0.5-2hrs. ESRF: 9hrs

1-2hours, metab upto 24hrs

Adverse Effects Toxicity

metabolic acidosis, urinary alkalinisation, parathesias, fatigue,
hypokalaemia, N+V, abdo pain

Tox: Rashes, renal stones

↓ K+/Na+/Cl-/Ca++, Hyper- urea/glu/chol, Metabolic alkalosis
Tox: Deafness, Pancreatitis
BM depression
Interstitial nephritis (worse with aminoglycoside)

↑K+(esp in renal failure). N/V and GI disturbances
Menstr irreg, Gynaecomastia
↑digoxin conc.
↓pressor response
↑effects of CVS depressants

Class Group

Diuretic – Carbonic Anhydrase Inhibitor

Diuretic - Loop

Diuretic – Aldosterone antagonist

Indications Uses

Glaucoma
Miniere’s disease
Altitude sickness
Adjunct in epilepsy

Oedema of cardiac, renal or hepatic origin, Renal insufficency
Hypertension
Raised ICP
Hypercalcaemia

Oedema – CHF, cirrhosis with ascites, refractory. HTN, Nephrotic syndrome. With loop/thiazide to conserve K+, diagn of Conn's syndr

Introduction

Sulfonamide

Sulfonamide derivative

A synthetic steroid

Legacy Cicm Level

Level 3

Level 1

Level 3

Presentation

250mg white tablets
500mg vials for reconstitution

Photosensitive solution 10mg/ml
20/40/500mg tabs, Syrup

25/100mg tablets

Route And Dose

250-1000mg q6hrly
IV/PO

20-2000mg daily
PO/IV/SL/IM.

PO. 25-200mg/day